Browsing by Author "Bahl, A"

Now showing 1 - 13 of 13
  • Thumbnail Image
    Item
    Authors’ response
    (2016-06) Nair, V; Madan, H; Sofat, S; Ganguli, P; Jacob, M J; Datta, R; Bharadwaj, P; Sarkar, R S; Pandit, A J; Nityanand, S; Goel, P K; Garg, N; Gambhir, S; George, P V; Chandy, S; Mathews, V; George, O K; Talwar, K K; Bahl, A; Marwah, N; Bhatacharya, A; Bhargava, B; Airan, B; Mohanty, S; Patel, C D; Sharma, A; Bhatnagar, S; Mondal, A; Jose, J; Srivastava, A
  • Thumbnail Image
    Item
    Carcinoma esophagus: A rare primary malignancy for ocular metastasis.
    (2010-10) Pal, D; Bahl, A; Sharma, J B; Rao, R R
  • No Thumbnail Available
    Item
    The clinicopathological profile and treatment outcomes of stage IV lung cancer patients treated at a tertiary cancer center in India
    (Medip Academy, 2024-11) Shrivastav, G; Batra, S; Rohatgi, N; Gupta, A; Siddiqui, H; Arya, D; Bahl, A; Chaturvedi, H.
    Background: Non-small cell lung cancer (NSCLC) is a devastating disease that originates from a complex combination of genetic, environmental, and lifestyle factors. A prospective study was conducted at Max Hospital, Saket, New Delhi, to assess the above factors in stage IV lung cancer patients and determine the survival rate and quality of life (QOL) parameters post-administration of the recommended first-line therapy. Methods: The primary objective of the study was to determine progression-free survival (PFS) in stage IV lung cancer patients after receiving the first-line therapy. This study also evaluated the clinical and histopathological profile of patients, survival rate, and QOL parameters after the administration of first-line therapy, which includes chemotherapy, tyrosine kinase inhibitors (TKI), immunotherapy, and chemo-immunotherapy. Results: The study enrolled 85 patients (63 males, 22 females) with a mean age of 64.08�.3 years. The median PFS was 10.56 months, with a six-month survival rate of 74.3% and a one-year overall survival rate of 58.3%. Among stage IV lung cancer patients, adenocarcinoma was more common (64.71%), especially in females (86.36%) compared to males (57.14%). Out of 85 patients, 54 completed the QOL questionnaire at baseline and follow-up, showing significant improvement in QOL scores during follow-up (p<0.0001). Conclusions: This prospective study showed improvement in PFS compared to the studies already conducted in different parts of India. A notable trend of increase in NSCLC was observed among females. Improvement in QOL scores was observed in patients who received chemotherapy and TKI as the first-line therapy.
  • Thumbnail Image
    Item
    Congestive heart failure in Indians: How do we improve diagnosis & management.
    (2010-11) Reddy, S; Bahl, A; Talwar, K K
    Heart failure is a common cardiovascular disease with high morbidity and mortality. Unlike western countries where heart failure is predominantly a disease of the elderly, in India it affects younger age group. Important risk factors include coronary artery disease, hypertension, diabetes mellitus, valvular heart disease and cardiomyopathies. Plasma brain natriuretic peptide levels are helpful in the diagnosis of heart failure. Echocardiography is the primary imaging modality of choice, through recently cardiac magnetic resonance imaging (MRI) has been found to play an increasing role. Aim of management is to improve symptoms & enhance survival. Diuretics are important in relieving symptoms. Beta-blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers and adosterone antagonists improve survival in patients with impaired systolic function. Device therapy including cardiac resynchronization therapy and implantable cardiac defibrillators, though expensive are useful in selected patients. Unlike in patients with systolic heart failure where several therapies have been shown to improve survival, clinical trial results in diastolic heart failure have been disappointing and therapy in these patients is restricted to symptom improvement and risk factor control. Therapies like stem cell therapy are being evaluated in clinical trials and appear promising. Early diagnosis and appropriate therapy helps in reversing the process of remodelling and clinical improvement in most of the patients.
  • No Thumbnail Available
    Item
    Micronuclei evaluation of reduction in neoadjuvant chemotherapy related acute toxicity in locally advanced lung cancer: an indian experience.
    (2006-03-28) Bahl, A; Chander, S; Julka, P K; Rath, G K; Sharma, D N; Kumar, A; Nair, O
    BACKGROUND: Lung cancer is the most common cancer in the world accounting for 17.6% cancers worldwide. The AAR i n I ndian population varies f r om 0.98-15.55. The aim of t he present study was to analyze areduction in neoadjuvant chemotherapy related acute toxicity in locally advanced lung cancer (stage IIIA and III B) using Wobe Mugos E and its evaluation using micronuclei as a cytogenetic marker. Micronuclei, which are cytoplasmic fragments of DNA, have been used as a biological dosimeter to assess DNA damage. MATERIAL AND METHODS: Fourty patients of locally advanced NSCLC were randomized into two study groups between 2001-2003. One group received neoadjuvant chemotherapy using Cisplatin and Etoposide. The other group received neoadjuvant chemotherapy using Cisplatin and Etoposide along with Wobe Mugos E which is a proteolytic enzyme preparation. A study of micronuclei frequency was done pre and post chemotherapy in both groups. RESULTS: Thirty eight patients were available for final evaluation. Anemia was the most common hematological toxicity observed. Nausea and vomiting were the most common non -hematological toxicity seen. Wobe Mugos E was found to reduce the incidence of leucopenia (p = 0.005), nausea (p=0.004), vomiting (p= 0.003), sensory neuropathy (p = 0.032) and treatment related depression (p= 0.005). A reduction in micronuclei was seen in patients in patients on Wobe Mugos E. (p =0.01). CONCLUSION: Neo-adjuvant chemotherapy related acute toxicity is a major problem in patients with advanced lung cancer. A reduction in micronuclei frequency shows Wobe Mugos E to be effective in reducing chemotherapy related acute toxicity.
  • No Thumbnail Available
    Item
    Nurse and the people's health.
    (1978-07-01) Bahl, A
  • No Thumbnail Available
    Item
    Nursing as a career.
    (1978-10-01) Bahl, A
  • Thumbnail Image
    Item
    A rare case of accessory mitral valve tissue
    (Indian Association of Pathologists and Microbiologists, 2018-09) Vaiphei, K; Kumar, R; Bahl, A
  • Thumbnail Image
    Item
    Recurrent pilomatrix carcinoma of scalp treated by electron beam radiation therapy.
    (2010-04) Bhasker, S; Bajpai, V; Bahl, A; Kalyanakuppam, S
  • No Thumbnail Available
    Item
    Recurrent syncopal attacks in a lady with rheumatoid arthritis.
    (2004-10-30) Kubba, S; Bali, H K; Bahl, A; Nand Kumar, S
  • Thumbnail Image
    Item
    Role of neoadjuvant concurrent chemoradiation in locally advanced unresectable pancreatic cancer: A feasibility study at tertiary care centre.
    (2014-04) Kapoor, R; Khosla, D; Gupta, R; Bahl, A; Shukla, A K; Sharma, S C
    BACKGROUND: Pancreatic cancer has an extremely poor prognosis and prolonged survival is achieved only by resection with macroscopic tumor clearance. There is a strong rationale for a neoadjuvant approach, since a relevant percentage of pancreatic cancer patients present with non‑metastatic but locally advanced disease. The objective of the present study was to assess the effect of neoadjuvant chemoradiation therapy (NACRT) on tumor response, down staging and resection, toxicity and any survival advantage. MATERIALS AND METHODS: A prospective pilot study was carried out from January 2009 to June 2011 in which 15 patients of locally advanced unresectable pancreatic cancer were included. All patients were treated with NACRT protocol with oral Capecitabine and 3D conformal radiotherapy (3DCRT) of 30 Gy in 10 fractions. The patients were restaged 3 to 4 weeks after the completion of NACRT and explored for resection. RESULTS: Out of 15 patients, fourteen were evaluable. Four patients underwent surgery, 5 had partial response but remained unresectable, 2 patients had stable disease and 3 had progressive disease. Most of the toxicities were slight and were in grade 1 to 2. None of the patients developed grade 3 or 4 gastrointestinal or hematological toxicity. The median survival was 15 months for resected patients and 8.6 months for unresected patients, respectively. The 2 year actuarial overall survival was 34.6%. CONCLUSION: All patients with locally unresectable pancreatic cancer should be offered chemoradiation therapy, in hopes of down staging the tumor for possible resection and achieving higher survival.
  • Thumbnail Image
    Item
    Synchronous carcinoma breast with chronic myelogenous leukemia: A rare presentation.
    (2010-10) Bahl, A; Dhiman, A; Talwar, V; Doval, D C
  • Thumbnail Image
    Item
    Tumour necrosis factor-alpha promoter polymorphism and its association with viral dilated cardiomyopathy in Indian population: A pilot study.
    (2015-01) Mishra, B; Sharma, M; Sarkar, S; Bahl, A; Saikia, U N; Ratho, R K
    Purpose: Tumour necrosis factor-α (TNF-α), a pro-infl ammatory cytokine has been implicated in the pathophysiology of several viral infections. TNF-α promoter gene polymorphism is thus believed to play the modulating role in this disease pathogenesis. Several studies have shown the increased level of TNF-α in dilated cardiomyopathy (DCM). However, the role of the TNF-α promoter polymorphism is yet to be delineated in this regard. The present study for the fi rst time tried to explore the association of TNF-α gene polymorphism with DCM of viral aetiology. Materials and Methods: Eighteen histopathologically proven DCM cases with viral genome positivity and 17 healthy controls were genotyped using polymerase chain reaction of TNF-α promoter gene followed by restriction fragment length polymorphism to determine the SNPs of -238G/A, -308G/A, -857C/T and -863C/A. Results: Of the 18 DCM cases 4 (22.2%) were positive for adenovirus (AdV), 2 (11.1%) for enterovirus (EV) and 12 (66.7%) had co-infection. Six of the 18 DCM cases (35.3%) had -238G/A polymorphism, and 10 (55.5%) had -863 homozygous AA genotype. The association of these polymorphisms was statistically signifi cant as compared to controls (P < 0.05). Conclusions: The present pilot study suggests the possible association of TNFα -238G/A and -863C/A polymorphism with DCM of viral aetiology.